secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARROW, INC. (HROW)
CIK:        0001360214
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001493152-23-027344
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harrow Q2: record revenue $33.5M (+44% YoY), adj. EBITDA $11.0M (+144%); $69M equity offer, product acquisitions
--------------------------------------------------------------------------------

- Record revenues of $33.5M, up 44% YoY; GAAP net loss of $4.2M.
- Record adjusted EBITDA of $11.0M, up 144% YoY; core gross margin improved to 78% from 73%.
- Completed $69M common stock offering and expanded Oaktree loan from $100M to $112.5M.
- Acquired North American rights to VEVYE (dry eye drug) and Santen portfolio including FLAREX, NATACYN, TOBRADEX ST.
- Reaffirmed 2023 guidance: net revenue $135-143M, adjusted EBITDA $44-50M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1360214/000149315223027344/0001493152-23-027344-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1360214/000149315223027344/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-027344

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer